JP2024526836A5 - - Google Patents
Info
- Publication number
- JP2024526836A5 JP2024526836A5 JP2024503352A JP2024503352A JP2024526836A5 JP 2024526836 A5 JP2024526836 A5 JP 2024526836A5 JP 2024503352 A JP2024503352 A JP 2024503352A JP 2024503352 A JP2024503352 A JP 2024503352A JP 2024526836 A5 JP2024526836 A5 JP 2024526836A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cells
- acid sequence
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223450P | 2021-07-19 | 2021-07-19 | |
| US63/223,450 | 2021-07-19 | ||
| PCT/US2022/073850 WO2023004289A1 (en) | 2021-07-19 | 2022-07-18 | Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526836A JP2024526836A (ja) | 2024-07-19 |
| JP2024526836A5 true JP2024526836A5 (enExample) | 2025-07-25 |
Family
ID=84979747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503352A Pending JP2024526836A (ja) | 2021-07-19 | 2022-07-18 | Ｆａｎｃｉ、ｒａｄ５１、およびｐｂｋ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250073333A1 (enExample) |
| EP (1) | EP4373516A4 (enExample) |
| JP (1) | JP2024526836A (enExample) |
| KR (1) | KR20240046834A (enExample) |
| CN (1) | CN117957012A (enExample) |
| AU (1) | AU2022314048A1 (enExample) |
| CA (1) | CA3226965A1 (enExample) |
| IL (1) | IL310204A (enExample) |
| MX (1) | MX2024000941A (enExample) |
| WO (1) | WO2023004289A1 (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2134855A4 (en) * | 2007-03-12 | 2011-01-05 | Dana Farber Cancer Inst Inc | USES OF FANCI AND FANCI MODULATING AGENTS IN PROGNOSIS, DIAGNOSIS AND CANCER THERAPY |
| CN104066746B (zh) * | 2011-10-28 | 2017-12-05 | 肿瘤疗法科学股份有限公司 | Topk肽及包含它们的疫苗 |
| KR102415259B1 (ko) * | 2013-11-22 | 2022-06-30 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 조작된 고-친화도의 인간 t 세포 수용체 |
| US10335471B2 (en) * | 2015-08-28 | 2019-07-02 | Immatics Biotechnologies Gmbh | Method for treating cancer with activated T cells |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| WO2019069125A1 (en) * | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| US20240024438A1 (en) * | 2020-11-19 | 2024-01-25 | Board Of Regents, The University Of Texas System | Methods and compositions comprising mhc class peptides |
-
2022
- 2022-07-18 US US18/580,486 patent/US20250073333A1/en active Pending
- 2022-07-18 WO PCT/US2022/073850 patent/WO2023004289A1/en not_active Ceased
- 2022-07-18 KR KR1020247005490A patent/KR20240046834A/ko active Pending
- 2022-07-18 CA CA3226965A patent/CA3226965A1/en active Pending
- 2022-07-18 CN CN202280056678.4A patent/CN117957012A/zh active Pending
- 2022-07-18 AU AU2022314048A patent/AU2022314048A1/en active Pending
- 2022-07-18 MX MX2024000941A patent/MX2024000941A/es unknown
- 2022-07-18 EP EP22846774.2A patent/EP4373516A4/en not_active Withdrawn
- 2022-07-18 JP JP2024503352A patent/JP2024526836A/ja active Pending
- 2022-07-18 IL IL310204A patent/IL310204A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250188145A1 (en) | Tcr and peptides | |
| KR102618231B1 (ko) | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 | |
| US20250171560A1 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| US20220096546A1 (en) | Modified Cell Expansion and Uses Thereof | |
| JP2021521776A5 (enExample) | ||
| JP2022527635A (ja) | Ｍａｇｅ ａ４ ｔ細胞受容体 | |
| JP2018183175A (ja) | Ｗｔ−１に特異的なｔ細胞免疫治療 | |
| US20210100841A1 (en) | Presenting cell and use thereof in cell therapy | |
| JP2022513148A (ja) | Ｔ細胞の改変 | |
| US20210060069A1 (en) | Coupled redirected cells and uses thereof | |
| JP2017522859A (ja) | グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用 | |
| US20210024890A1 (en) | Modulating t cell function and response | |
| JP2022554395A5 (enExample) | ||
| US11161913B2 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| AU2019324162A1 (en) | Immunotherapy targeting KRAS or Her2 antigens | |
| JP2023513605A5 (enExample) | ||
| JP2023528255A5 (enExample) | ||
| CN110511912A (zh) | 免疫细胞的功能调节 | |
| CN111826353A (zh) | 调节t细胞功能和反应的方法 | |
| EP3892720A1 (en) | Presenting cell and use thereof in cell therapy | |
| JP2024526836A5 (enExample) | ||
| JP2024516542A5 (enExample) | ||
| JP2024517630A5 (enExample) | ||
| JP2022554349A5 (enExample) | ||
| CA3125646A1 (en) | Modified cell expansion and uses thereof |